Breast Cancer Diagnosis Process: An Integrative Evaluation of Five Components

Abstract

provide RWD on the use of BV in the treatment of HL in a private healthcare setting in Brazil. Methods: This retrospective analysis collected data from Evidencias-Kantar Health claims database (Auditron, which covers 3+ million lives, ~7% of Brazilian private sector) between March/2013-March/2016 on demographic, diseaserelated and treatment-related parameters regarding patients diagnosed with HL. Data were summarized using descriptive statistics. Results: We found 147 HL patients, being 51.7% female, with median age of 32 years (IQR:25-41). The number of patients that received each therapy line was: 147, 42, 29, 20, 9, 5, 3, 2 and 1 for first to ninth-line respectively. From the third-line forward, BV was present among the chosen therapies. Of the 15 patients treated with BV (1 patient received it in 3 lines), 60% were male, 43% on stage IV disease, had a median age of 30 years (IQR:28-39) and a median number of cycles of 3 (IQR:3-4). Distribution of patients (number of patients/total number of patients per line) that received BV in each line was: thirdline (1/20); fourth-line (7/20, with one patient receiving BV in combination with gemcitabine+liposomal doxorubicin); fifth-line (4/9); sixth-line (3/5); seventh-line (1/3); eighth-line (1/2). Overall, 10.2% of the patients with HL were treated with BV and only one received SCT (heterologous) in fourth-line. ConClusions: RWD from this cohort of HL from Auditron demonstrates 20% of patients with HL received at least 3 lines of treatment. The rate of patients treated with BV increased, as the lines of therapy advanced and 10.2% received the drug at some point in treatment.